Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-α in Chronic Hepatitis C

Chemello, Liliana; Cavalletto, Luisa; Casarin, Carla; Bonetti, Paola; Bernardinello, Elisabetta; Pontisso, Patrizia; Donada, Carlo; Belussi, F.; Martinelli, Silio; Alberti, Alfredo

doi:10.7326/0003-4819-124-12-199606150-00005

Cited by 99 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term follow-up studies showed that the vast majority of the sustained virologic responders are probably cured from HCV infection. [44][45][46] HCV resistance is defined as HCV RNA persistence in serum after therapy. The incidence of HCV resistance to IFN-based therapies varies according to the administered regimen.…”

Section: Definitions: Incidence and Patterns Of Hcv Resistance To Antmentioning

confidence: 99%

Hepatitis C Virus Resistance to Antiviral Therapy

Pawlotsky

2000

Hepatology

123

View full text Add to dashboard Cite

Section: Definitions: Incidence and Patterns Of Hcv Resistance To Antmentioning

confidence: 99%

Hepatitis C Virus Resistance to Antiviral Therapy

Pawlotsky

2000

Hepatology

123

View full text Add to dashboard Cite

“…[10][11][12] They thus concluded that in patients with chronic hepatitis C who have no detectable serum HCV RNA 24 weeks after interferon therapy, longterm sustained biochemical and virologic response is anticipated. However, whether HCV SVR24 could be maintained in patients with chronic hepatitis B and C coinfection has not been reported.…”

mentioning

confidence: 99%

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Lee

Chen

et al. 2013

Hepatology

View full text Add to dashboard Cite

Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCVmonoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n 5 97) and HBVmonoinfected (n 5 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n 5 64) and monoinfected (n 5 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 6 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1/HBV-coinfected patients and one HCV genotype 2/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group. Conclusion: Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. (HEPATOLOGY 2013;57:2135-2142

show abstract

“…Hepatitis C-Reports describing the results of controlled trials suggested that interferon alpha therapy was associated with a 50% biochemical response rate, a 50% relapse rate in responders, and a sustained response rate of 25% (95). Patients who do not respond to therapy within the first 3 months are unlikely to respond thereafter.…”

Section: Treatment Of Viral Hepatitismentioning

confidence: 99%

Update in Internal Medicine

López-Jiménez

Brito

Aude

et al. 2000

Archives of Medical Research

View full text Add to dashboard Cite

More than 500,000 new medical articles are published every year and available time to keep updated is scarcer every day. Nowadays, the task of selecting useful, consistent, and relevant information for clinicians is a priority in many major medical journals. This review has the aim of gathering the results of the most important findings in clinical medicine in the last few years. It is focused on results from randomized clinical trials and well-designed observational research. Findings were included preferentially if they showed solid results, and we avoided as much as possible including only preliminary data, or results that included only non-clinical outcomes.Some of the most relevant findings reported here include the significant benefit of statins in patients with coronary artery disease even with mean cholesterol level. It also provides a substantial review of the most significant trials assessing the effectiveness of IIb/IIIa receptor blockers. In gastroenterology many advances have been made in the H. pylori eradication, and the finding that the cure of H. pylori infection may be followed by gastroesophageal reflux disease. Some new antivirals have shown encouraging results in patients with chronic hepatitis. In the infectious disease arena, the late breaking trials in anti-retroviral disease are discussed, as well as the new trends regarding antibiotic resistance. This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine.

show abstract

Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-α in Chronic Hepatitis C

Abstract: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-alpha therapy to determine whether the response is complete and permanent.

Cited by 99 publications

References 0 publications

Hepatitis C Virus Resistance to Antiviral Therapy

Hepatitis C Virus Resistance to Antiviral Therapy

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Update in Internal Medicine

Contact Info

Product

Resources

About